Company performance
Add to research
Current Price
as of Mar 13, 2025$73.02
P/E Ratio
N/A
Market Cap
$9.58B
Loading...
Description
Add to research
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.
Metrics
Add to research
Overview
- HQSan Carlos, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerPCVX
- Price$73.02-0.30%
Trading Information
- Market cap$9.58B
- Float97.17%
- Average Daily Volume (1m)1,291,446
- Average Daily Volume (3m)1,189,431
- EPS-$3.80
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$463.93M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$553.70M
- EV$8.31B
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B2.76
- Debt/Equity2.15
Documents
Add to research
SEC Filings
Factset Street Account